Format

Send to

Choose Destination
Transplantation. 2012 Feb 15;93(3):241-3. doi: 10.1097/TP.0b013e31823aa56e.

The once-daily formulation of tacrolimus: a step forward in kidney transplantation?

Author information

1
Department of Nephrology, Clinique Universitaire Hôpital Erasme, Renal Transplantation Clinic, Brussels, Belgium. jehougar@ulb.ac.be

Abstract

Nonadherence is a critical issue in transplantation. Recently, Astellas designed a once-daily-extended release formulation of tacrolimus (Tac). Despite initial reports showing bioequivalence of Tac once-daily (Advagraf) with the original formulation requiring twice-daily intake (Tac twice-daily, Prograf), several groups have now shown a sustained decrease in Tac exposure upon conversion from Prograf to Advagraf. Here, we discuss the possible reasons for this observation and how it could affect the expected benefits of Advagraf, and we comment on the fact that a similar lack of bioequivalence might prevail with generic immunosuppressive drugs.

PMID:
22234346
DOI:
10.1097/TP.0b013e31823aa56e
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center